503A vs 503B: know who made your compounded peptide before you use it

Proposed URL: peptidex.ai/503a-vs-503b. Last checked: November 4, 2026. Educational only, not legal or medical advice.

The kind of compounder behind a peptide decides which quality rules applied to it, and whether FDA ever inspects the facility. Here's the difference in one table.

Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before they are marketed [FR].

Short answer

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act cover two kinds of compounders. 503A covers state-licensed pharmacists and physicians who compound based on a valid patient-specific prescription [FDA-LAWS]. 503B covers "outsourcing facilities" that elect to register with FDA, must follow current good manufacturing practice (CGMP) and are inspected by FDA on a risk-based schedule [FDA-OF]. The HHS peptide item published in the Federal Register on October 30, 2026 is a draft policy that concerns 503A compounding only [FR].

Side by side

503A (pharmacist or physician)503B outsourcing facility
WhoState-licensed pharmacist or physician [FDA-503A]A facility at one location that compounds sterile drugs, has elected to register as an outsourcing facility and meets all 503B requirements [FDA-OF]
PrescriptionMust be based on a valid patient-specific prescription [FDA-LAWS]A patient-specific prescription, or a provider order (such as a hospital's) that isn't for an identified patient, e.g. office stock [FDA-LAWS]
Quality standardExempt from federal CGMP requirements when 503A conditions are met [FDA-LAWS]Must meet CGMP; FDA inspects on a risk-based schedule; must report adverse events and product information to FDA [FDA-OF]
Bulk ingredientsMust meet a USP/NF monograph if one exists; otherwise be a component of an FDA-approved drug; otherwise be on the 503A bulks list [FDA-503A]Must be on the 503B bulks list, or the drug must be on FDA's drug shortage list at the time [FDA-503B]
Interim categoriesFDA interim policy Categories 1, 2, 3 for nominated substances [FDA-503A]Separate interim Categories 1, 2, 3 [FDA-503B]
FDA approval of the finished drugNo (exempt from approval requirements) [FDA-LAWS]No (can qualify for exemption from approval requirements) [FDA-OF]

What the "bulks list" and Categories 1, 2 and 3 mean

  • 503A bulks list: bulk drug substances a 503A compounder may use when there's no USP/NF monograph and the substance isn't part of an FDA-approved drug. Substances are added through notice-and-comment rulemaking [FDA-503A].
  • Category 1: nominated with enough supporting information for FDA to evaluate, may be eligible for the bulks list, and on no other list. FDA does not intend to take action against compounding with these substances, provided the conditions in its guidance are met [FDA-503A][FDA-503B].
  • Category 2: nominated with enough information to evaluate, but FDA has identified significant safety risks. These are outside the Category 1 policy, and FDA would consider taking action under its general enforcement policies [FDA-503A][FDA-503B].
  • Category 3: nominated without enough supporting information for FDA to evaluate. These can be re-nominated, aren't covered by the Category 1 policy, and FDA would consider taking action [FDA-503A][FDA-503B].
  • New nominations: FDA says it does not intend to place substances nominated on or after January 7, 2025 into these categories [FDA-503A][FDA-503B].
  • Peptides: FDA's current list of Category 2 substances includes several peptides (for example, ipamorelin acetate and GHRP-6 under 503B, and kisspeptin-10 under 503A). BPC-157 was previously in Category 2. FDA now lists it under "nominated but withdrawn" [FDA-CAT2]. See our tracker: /blog/fda-category-2-peptides-2026.

Where the HHS peptide item fits

  • What it is: a notice of availability for a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," FR Doc. 2026-22192 (91 FR 68526), published October 30, 2026. It applies to the peptides in its Appendix A [FR].
  • What it is not: it is not FDA approval of any peptide and does not add anything to the 503A bulks list. HHS says the policy is not binding and may be revisited if a safety or quality issue arises. Its title and text address 503A compounding only [FR].
  • Status as of Nov 4, 2026: draft. Public comments are open for two weeks from publication [FR]. Track updates at /hhs-503a-peptides.

FAQ

Is 503B "better" than 503A? They follow different rules. 503B facilities must meet CGMP and are FDA-inspected on a risk-based schedule. 503A compounding is exempt from CGMP when 503A conditions are met [FDA-LAWS][FDA-OF]. Neither one makes the finished drug FDA-approved.

Does the HHS peptide policy change what 503B facilities can do? Its title and text address 503A compounding only. It's a draft [FR].

Is a compounded GLP-1 the same as an FDA-approved GLP-1 drug? No. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed [FR]. Compounded drugs are not FDA-approved. See /compounded-semaglutide-status.

Could a compounded peptide be right for me? Only a licensed clinician can tell you whether you may qualify for a prescription. We don't make claims about results.

Sources (checked Nov 4, 2026)

PeptideX is a service of VitalBridgeX Holdings LLC. Compounded drugs are not FDA-approved. Talk with a licensed clinician about your situation.

Related: Compounded tirzepatide status